Pulmonx Corporation (LUNG)
$
3.2
+0.24 (7.50%)
Key metrics
Financial statements
Free cash flow per share
-0.8575
Market cap
128.8 Million
Price to sales ratio
1.4727
Debt to equity
0.7332
Current ratio
4.9685
Income quality
0.5774
Average inventory
16.9 Million
ROE
-0.6369
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Pulmonx Corporation, a medical technology company founded in 1995 and based in Redwood City, California, specializes in developing minimally invasive devices aimed at treating chronic obstructive pulmonary diseases. The company has made notable advancements with products such as the Zephyr Endobronchial Valve, designed for adult patients experiencing hyperinflation due to severe emphysema. Furthermore, Pulmonx offers the Chartis Pulmonary Assessment System, which utilizes a balloon catheter and console system equipped with flow and pressure sensors to evaluate collateral ventilation. In addition, the StratX Lung Analysis Platform, a cloud-based service, provides quantitative computed tomography analysis to assist in determining emphysema destruction, fissure completeness, and lobar volume, thereby aiding in identifying target lobes for Zephyr Valve treatment. The earnings per share (EPS) is reported at -$1.44 indicating the company's profitability on a per-share basis. The operating income ratio is -0.69 indicating the company's operational profitability margin. Moreover, the income before tax ratio is -0.67 reflecting the pre-tax margin. The EBITDA ratio stands at -0.61 highlighting the company's operational efficiency. The company achieved a revenue of $83,789,000.00 indicating its niche market focus. Moreover, Pulmonx operates in a market characterized by its affordability; the stock is priced at $3.20 making it suitable for budget-conscious investors. Notably, the stock has a low average trading volume of 355,282.00 suggesting lower market activity, which may appeal to certain investor strategies. With a market capitalization of $128,824,000.00 the company is classified as a small-cap player within the industry. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth in its field, thereby reinforcing the company's position and influence in the medical technology arena.
Is Pulmonx Corporation (LUNG) a good investment?
Investing in Pulmonx Corporation (LUNG) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Pulmonx Corporation (LUNG)'s stock forecast?
Analysts predict Pulmonx Corporation stock to fluctuate between $2.83 (low) and $9.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Pulmonx Corporation's market capitalization?
As of 2025-05-30, Pulmonx Corporation's market cap is $128,824,000, based on 40,257,500 outstanding shares.
How does Pulmonx Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Pulmonx Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Pulmonx Corporation (LUNG) stock?
To buy Pulmonx Corporation (LUNG) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LUNG. Place an order (Market, Limit, etc.).
What is the best time to invest in Pulmonx Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Pulmonx Corporation perform in the last earnings report?
Revenue: $83,789,000 | EPS: -$1.44 | Growth: -10%.
Where can I find Pulmonx Corporation's investor relations reports?
Visit https://pulmonx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Pulmonx Corporation?
You can explore historical data from here
What is the all-time high and low for Pulmonx Corporation stock?
All-time high: $63.83 (2021-03-11) | All-time low: $2.83 (2025-05-28).
What are the key trends affecting Pulmonx Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
2 days ago
REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET.
globenewswire.com
a month ago
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET.
seekingalpha.com
a month ago
Pulmonx Corporation (NASDAQ:LUNG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Laine Morgan - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
zacks.com
a month ago
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.36 per share a year ago.
globenewswire.com
a month ago
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025.
prnewswire.com
2 months ago
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis.
globenewswire.com
3 months ago
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. “We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS.
seekingalpha.com
3 months ago
Pulmonx Corporation (NASDAQ:LUNG ) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx Fourth Quarter 2024 Earnings Conference Call.
zacks.com
3 months ago
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.36 per share a year ago.
globenewswire.com
3 months ago
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.
See all news
